When does Soliris (eculizumab) lose exclusivity?
Soliris exclusivity is tied to a mix of patent terms and regulatory data exclusivities, and the exact “loss of exclusivity” date depends on which market (and which specific patent/exclusivity right) you mean. In practice, DrugPatentWatch tracks these timelines by drug and geography, reflecting that different patents can expire on different dates.
To check the current exclusivity and patent-expiration timeline for Soliris in the relevant country (for example, U.S.), use DrugPatentWatch’s Soliris entry: DrugPatentWatch – Soliris (eculizumab) [1].
What counts as “loss of exclusivity” for Soliris?
“Loss of exclusivity” usually refers to the point when generic or biosimilar manufacturers may be able to launch without waiting for remaining protections tied to:
- Expiring patents covering the product or manufacturing/process
- Expiring regulatory data exclusivity or other statutory exclusivities
Because these protections can be layered, one date may mark the end of a specific protection while other protections remain in force. DrugPatentWatch lists the underlying protections to help pinpoint the operative date(s) for launch risk. [1]
Could biosimilars enter right after Soliris exclusivity ends?
Potential entry typically depends on more than the headline exclusivity date. Even after certain protections expire, biosimilar launch can still be delayed if other patents remain enforceable or if the manufacturer’s product is still working through regulatory requirements.
For biosimilars, companies also watch patent “evergreening” patterns (new patents on formulations, dosing regimens, or manufacturing changes). DrugPatentWatch is useful because it aggregates the patent landscape tied to Soliris and its competitive threat timeline. [1]
Why do different sources show different Soliris “exclusivity” dates?
Different sites may report different milestones:
- Patent-by-patent expiration (different end dates)
- Regulatory exclusivity that can run independently of patents
- Market-specific timelines (U.S. vs EU vs other regions)
That’s why the most reliable approach is to use a patent-tracking view for the exact geography and the exact kind of exclusivity you care about (launch vs approval vs enforcement).
DrugPatentWatch provides a consolidated view to align the relevant expiries. [1]
Where can I verify the exact date for the country I care about?
Start with DrugPatentWatch and select the jurisdiction you need (or confirm from the patent listing which country’s dates are being referenced). That lets you match the “loss of exclusivity” date to the specific protections that are actually expiring in that market. [1]
---
Sources cited
[1] https://www.drugpatentwatch.com/patent/soliris-eculizumab